A calcium channel blocker signal in heart failure with advanced kidney disease, and why the title outruns it

Design

retrospective cohort with multivariable Cox regression and inverse probability treatment weighting

Population

1,835 patients with heart failure and eGFR 30 mL/min/1.73 m2 or below at one tertiary centre

Primary outcome

all-cause mortality from a national registry

Effect

weighted HR 0.85 (95% CI 0.73-0.99); unadjusted HR 0.83 (0.74-0.93)

A tertiary centre followed 1,835 consecutive patients with heart failure and an eGFR of 30 mL/min/1.73 m2 or below between 2014 and 2025. Just over half were on a calcium channel blocker at baseline, 45% of them dihydropyridines. Median follow-up was 1.68 years and 69.7% died.

Calcium channel blocker use was associated with lower all-cause mortality, hazard ratio 0.83 (95% CI 0.74-0.93) unadjusted and 0.85 (0.73-0.99) after inverse probability of treatment weighting. The association held across heart failure phenotypes and in the diabetes and hypertension subgroups. In subclass analysis the non-dihydropyridine agents carried the significant association and the dihydropyridines did not - which is the opposite of what most physicians would predict, since non-dihydropyridines are the ones avoided in reduced ejection fraction for their negative inotropy.

That inversion is the reason to be careful rather than reassured. This is an observational cohort in which the patients prescribed a calcium channel blocker are, by definition, the ones a clinician judged well enough to need blood pressure control - and weighting adjusts for what was recorded, not for that judgement. The paper's title asserts safety and benefit; the design supports neither. Read it as a reason not to reflexively stop a calcium channel blocker in this group, and not as a reason to start one.

• Do not reflexively deprescribe a calcium channel blocker in heart failure with advanced kidney disease.
• This is not a reason to start one - the design cannot support a treatment decision.
• Non-dihydropyridines carried the association, which conflicts with their usual caution in reduced ejection fraction.
• Mortality in this cohort was 69.7% over a median 1.68 years; these are very sick patients.
• Where blood pressure control is needed and options are few, this makes the existing prescription easier to defend.

Why it matters

It pushes back on a common reflex to strip calcium channel blockers out of the list when kidney function falls, without giving a reason to add one.

Don't overread it

Observational and single-centre - an association with survival here is far more likely to reflect who was prescribed the drug than what the drug did.

The statistics, in plain English

The weighted hazard ratio of 0.85 has an upper confidence limit of 0.99, so the result only just clears conventional significance, and in observational work that is a fragile place to be. The deeper problem is confounding by indication: clinicians prescribe antihypertensives to patients well enough to tolerate them, and no statistical adjustment recovers the judgement that is not written in the record.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.